3 Key Takeaways
Plain English Summary- 01Core Finding
In this prospective study, we consecutively acquired and examined submandibular gland biopsies from patients with clinical PD in neurologic care and controls who underwent surgical procedures on the submandibular gland for different reasons.
- 02Study Evidence
Tested in a observational cohort study (n = 41) at the real-world cohort stage.
- 03Practical Meaning
Observational cohort findings reveal real-world links, though lifestyle or unmeasured factors cannot be fully ruled out without an RCT.
What This Means for You
With a sensitivity of more than 80%, which is comparable with the clinical diagnosis when neuropathologic examination serves as gold standard, the RT-QuIC assay on salivary gland biopsies may serve as a valuable instrument to improve the diagnosis of PD. Further validation is necessary to substantiate these findings in larger-scale investigations.
The Discovery
The definite diagnosis of Parkinson disease (PD) is usually made by the detection of α-synuclein aggregates in the brain postmortem with the rare exception of some genetic forms. Traces of α-synuclein aggregates in extracerebral tissue biopsies may serve as an appropriate biomarker (measurable biological signal) to confirm a clinical diagnosis in vivo. We set out to determine whether the detection of α-synuclein aggregates in submandibular gland biopsies is an effective means for diagnosing patients with PD. In this prospective study, we consecutively acquired and examined submandibular gland biopsies from patients with clinical PD in neurologic care and controls who underwent surgical procedures on the submandibular gland for different reasons. Our index method was the detection of α-synuclein aggregates using the real-time quaking-induced conversion (RT-QuIC) in fresh-frozen tissue. We compared the results with immunohistochemical α-synuclein aggregate detection and paraffin-embedded tissue blot (PET-blot) as reference methods in formalin-fixed tissue from the same biopsy. The study population included 25 patients with clinical PD (mean age 67.3 ± 9.3 years, 64% male, 36% female) and 25 age-matched controls (mean age 64.6 ± 8.6 years, 48% male, 52% female). The RT-QuIC assay detected α-synuclein aggregates in submandibular gland biopsies (n = 41) with a sensitivity, which increased to 90% after a clinical follow-up, and a specificity of 100%, thus providing an accuracy of 90.2% (95% CI 76.6%-96.4%) and 95.1% (95% CI 82.9%-98.7%), respectively. The PET-blot with mAb5C12 (n = 49) confirmed 50% of the RT-QuIC positives and offered a sensitivity of 45.8% (50% after clinical follow-up) and a specificity of 100%. Immunohistochemical detection (n = 48) using the same antibody confirmed 28% of the RT-QuIC positives but found 2 of the controls to be positive and therefore provided a sensitivity of 26.1% (28.6% after clinical follow-up) and a specificity of 92%.
How It Works, Simply
This neurology research focuses on antibodies · Immune response · Blood biomarker (measurable biological signal). Researchers evaluated it using an observational cohort study (n = 41) at the real-world cohort stage of medical research.
3 Key Takeaways
Clinical Takeaways- 01Core Finding
In this prospective study, we consecutively acquired and examined submandibular gland biopsies from patients with clinical PD in neurologic care and controls who underwent surgical procedures on the submandibular gland for different reasons.
- 02Study Evidence
Tested in a observational cohort study (n = 41) at the real-world cohort stage.
- 03Practical Meaning
Observational cohort findings reveal real-world links, though lifestyle or unmeasured factors cannot be fully ruled out without an RCT.
Key Numbers
Biological Mechanism & Study Design
Study Design & Cohort
Observational cohort study
Observational cohort study (n = 41) · Real-World Cohort
Biological Pathway & Modality
Antibodies · Immune response · Blood biomarker
Intervention: Evaluation of Submandibular Gland Biopsies With Real-Time Quaking-Induced Conversion
Experimental Findings & Endpoints
The definite diagnosis of Parkinson disease (PD) is usually made by the detection of α-synuclein aggregates in the brain postmortem with the rare exception of some genetic forms.
Traces of α-synuclein aggregates in extracerebral tissue biopsies may serve as an appropriate biomarker to confirm a clinical diagnosis in vivo. We set out to determine whether the detection of α-synuclein aggregates in submandibular gland biopsies is an effective means for diagnosing patients with PD.
In this prospective study, we consecutively acquired and examined submandibular gland biopsies from patients with clinical PD in neurologic care and controls who underwent surgical procedures on the submandibular gland for different reasons. Our index method was the detection of α-synuclein aggregates using the real-time quaking-induced conversion (RT-QuIC) in fresh-frozen tissue.
We compared the results with immunohistochemical α-synuclein aggregate detection and paraffin-embedded tissue blot (PET-blot) as reference methods in formalin-fixed tissue from the same biopsy. The study population included 25 patients with clinical PD (mean age 67.3 ± 9.3 years, 64% male, 36% female) and 25 age-matched controls (mean age 64.6 ± 8.6 years, 48% male, 52% female).
The RT-QuIC assay detected α-synuclein aggregates in submandibular gland biopsies (n = 41) with a sensitivity, which increased to 90% after a clinical follow-up, and a specificity of 100%, thus providing an accuracy of 90.2% (95% CI 76.6%-96.4%) and 95.1% (95% CI 82.9%-98.7%), respectively. The PET-blot with mAb5C12 (n = 49) confirmed 50% of the RT-QuIC positives and offered a sensitivity of 45.8% (50% after clinical follow-up) and a specificity of 100%.
Immunohistochemical detection (n = 48) using the same antibody confirmed 28% of the RT-QuIC positives but found 2 of the controls to be positive and therefore provided a sensitivity of 26.1% (28.6% after clinical follow-up) and a specificity of 92%.
Clinical Translation & Practice Context
With a sensitivity of more than 80%, which is comparable with the clinical diagnosis when neuropathologic examination serves as gold standard, the RT-QuIC assay on salivary gland biopsies may serve as a valuable instrument to improve the diagnosis of PD.
Further validation is necessary to substantiate these findings in larger-scale investigations.
The Bottom Line · Clinical Pearl
“With a sensitivity of more than 80%, which is comparable with the clinical diagnosis when neuropathologic examination serves as gold standard, the RT-QuIC assay on salivary gland biopsies may serve as a valuable instrument to improve the diagnosis of PD. Further validation is necessary to substantiate these findings in larger-scale investigations.”
Published in Neurology · Current Stage: Real-World Cohort
